Table 3.
General information and characteristics of candidiasis described for Candida inconspicua.
| Invasive/Noninvasive Candidiasis (n Human Cases/Strains/Isolates) |
Identification Methods |
Imaging Test |
Antifungal Susceptibility |
Antifungal Resistance |
Antifungal Treatment |
Other Treatments (e.g., Probiotics, Natural Compounds, Antivirals) |
Outcome (n) |
Reference(s) |
|---|---|---|---|---|---|---|---|---|
| (noninvasive) Sample collected from alcoholic beverages (n = NR) |
PCR, Sequencing, Enzyme profiling | NR | Amphotericin B and micafungin | Itraconazole, fluonazole, |
Itraconazole, fluconazole, amphotericin B and micafungin | No | NA | [40] |
| (invasive and noninvasive) Samples from oral cavity, anal/stools, urine respiratory, blood/catheter (n = 12) |
Ellipsometer test, MIC | NR | Caspofungin | Fluconazole-resistant | Itraconazole, voriconazole, posaconazole isavuconazole, fluconazole, amphotericin B and caspofungin | Broad-spectrum antibiotic |
Died (n = 1) |
[42] |
| (invasive) Blood sample (n = 2) |
MIC, Fungicidal and fungistatic activity | NR | Echinocandins | Azoles | Fluconazole, caspofungin | No | NA | [43] |
| (invasive) Systemic mycosis (n = 168) |
Antifungal susceptibility and Ellipsometer test, MALDI-TOF MS | NR | Susceptible to echinocandins, polyenes | Azoles | Itraconazole, voriconazole, posaconazole, isavuconazole, fluconazole, Caspofungin, micafungin, anidulafungin, Amphotericin B, |
No | NA | [44] |
MIC: Minimal inhibitory concentrations; NA: Not applicable, because the research is performed on fungal strains/clinical isolates; NR: Not reported; MALDI-TOF MS: matrix-assisted laser desorption ionization mass spectrometry.